Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Prog Urol ; 27(5): 275-282, 2017 Apr.
Article in French | MEDLINE | ID: mdl-28365198

ABSTRACT

OBJECTIVE: Combination of alpha-blockers with potent CYP3A4 inhibitors is either contra-indicated or not recommended. We searched data supporting this classification and guiding prescribers when such an interaction occurs. METHODS: We analyzed reports published by the French agency for drug safety, reference books and performed search in databases of pharmacokinetics studies and case or case series related with these interactions. RESULTS: The classification of the potential severity of these interactions defined by the French agency for drug safety evolved over time. Our literature search did not identify any cases or case series reporting serious clinical consequences of such interactions and no pharmacoepidemiological studies on the association between alpha-blockers and inhibitors of CYP3A4. The content of the summaries of product characteristics indicate that the combination of ketoconazole with alfuzosin, silodosin and tamsulosin increases the area under the curve of the alpha-blocker 3 fold. CONCLUSION: Data demonstrating the clinical consequences of an association between alpha-blocker and a potent CYP3A4 inhibitor are lacking. The 3 fold increase of the area under the curve for alfuzosin, silodosin and tamsulosin associated with ketoconazole while the association with the two first is contra-indicated and is not recommended with the third raises questions. This lack of data leaves doctors and pharmacists in a situation of uncertainty on how to proceed when such an interaction occurs.


Subject(s)
Adrenergic alpha-Antagonists/pharmacokinetics , Cytochrome P-450 CYP3A Inhibitors/pharmacokinetics , Drug Interactions , Indoles/pharmacokinetics , Ketoconazole/pharmacokinetics , Quinazolines/pharmacokinetics , Sulfonamides/pharmacokinetics , Adrenergic alpha-Antagonists/pharmacology , Cytochrome P-450 CYP3A Inhibitors/pharmacology , Drug Therapy, Combination/adverse effects , France , Government Agencies , Humans , Indoles/pharmacology , Ketoconazole/pharmacology , Quinazolines/pharmacology , Sulfonamides/pharmacology , Tamsulosin
2.
J Hazard Mater ; 158(2-3): 430-7, 2008 Oct 30.
Article in English | MEDLINE | ID: mdl-18329797

ABSTRACT

In this work, the electrochemical oxidation on boron-doped diamond of synthetic wastes polluted with surfactant sodium dodecylbenzenesulfonate (SDBS) has been studied. Results show that SDBS can be successfully removed with this technology inside different current densities and concentration ranges. The oxidation of the SDBS seems to occur in two main sequential steps: the first is the rapid degradation of SDBS, and the final is the less efficient oxidation of aliphatic intermediates to carbon dioxide. The nature of supporting electrolyte (NaCl, Na(2)SO(4) and K(3)PO(4)) influences on the efficiency of the electrochemical oxidation process. The treatment of the NaCl solution seems to be more efficient in the chemical oxygen demand (COD) removal, while the sulphate and specially the phosphate media improve the TOC removal. However, in spite of this observation, chemical oxidation of SDBS by different types of oxidants cannot explain alone the results of the electrochemical oxidation with diamond anodes. This suggests that the synergistic effect of the different oxidation mechanisms that occurs into the electrochemical cell (direct oxidation and mediated oxidation by hydroxyl radicals and by oxidants formed from the electrolyte) is the responsible of the great efficiencies obtained with this technology in the treatment of organics.


Subject(s)
Anions/chemistry , Boron/chemistry , Electrochemistry , Electrodes , Surface-Active Agents/chemistry , Oxidation-Reduction
SELECTION OF CITATIONS
SEARCH DETAIL
...